Virtus LifeSci Biotech Clinical Trls ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Virtus LifeSci Biotech Clinical Trials ETF BBC
Morningstar’s Analysis BBC
Will BBC outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 14.2
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Kodiak Sciences Inc | 2.08 | 879,991 | Healthcare |
AbCellera Biologics Inc Ordinary Shares | 1.97 | 832,094 | Healthcare |
Xencor Inc | 1.51 | 639,307 | Healthcare |
Amylyx Pharmaceuticals Inc | 1.43 | 604,432 | Healthcare |
First Tracks Biotherapeutics Inc | 1.41 | 598,674 | Healthcare |
MBX Biosciences Inc | 1.23 | 522,845 | Healthcare |
4D Molecular Therapeutics Inc Ordinary Shares | 1.16 | 491,272 | Healthcare |
Definium Therapeutics Inc Ordinary Shares | 1.13 | 479,543 | Healthcare |
SELLAS Life Sciences Group Inc | 1.12 | 475,799 | Healthcare |
ORIC Pharmaceuticals Inc | 1.11 | 468,330 | Healthcare |